The Rise and Fall of Oral Ketoconazole

@article{Gupta2015TheRA,
  title={The Rise and Fall of Oral Ketoconazole},
  author={Aditya K. Gupta and Danika C A Lyons},
  journal={Journal of Cutaneous Medicine and Surgery},
  year={2015},
  volume={19},
  pages={352 - 357}
}
Background: Ketoconazole was the first broad-spectrum oral antifungal agent available to treat systemic and superficial mycoses. Evidence of hepatotoxicity associated with its use emerged within the first few years of its approval. Growing evidence of serious side effects including endocrine dysregulation, several drug interactions, and death led to the review of oral ketoconazole in 2011. Objective: This article chronicles the use of oral ketoconazole from its introduction to its near… Expand
Topical ketoconazole: a systematic review of current dermatological applications and future developments
TLDR
Topical KTZ is clinically effective for the treatment of Malassezia-related conditions such as seborrheic dermatitis (SD) and pityriasis versicolor (PV) with a reported efficacy of 63–90% and 71–89%, respectively. Expand
Systemic Antifungal Agents: Current Status and Projected Future Developments.
TLDR
This chapter focuses on the currently available classes and representatives of systemic antifungal drugs in clinical use, and develops new drugs with novel targets for treatment of invasive fungal infections, including nikkomycin Z, sordarin derivatives, VT-1161 and VT-1129. Expand
Systemic ketoconazole continues to be prescribed despite an FDA warning.
Oral ketoconazole is not recommended as an antifungal medication for skin infections due to its poor efficacy and its potential for significant side effects (1–3). In July of 2013, the United State...
Antifungal resistance in dermatophytes: recent trends and therapeutic implications.
TLDR
This review provides a comprehensive account of the available literature on in-vitro resistance to clinically used antifungals among dermatophytes and apprise the readers of the relevant skin pharmacokinetics of each. Expand
Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going?
TLDR
This review aims to discuss the aspects related to the identification of compounds, methodologies, and perspectives when proposing new antifungal agents against PCM. Expand
Antifungal Use in Veterinary Practice and Emergence of Resistance
TLDR
The management of fungal infections in animals usually includes systemic or topical treatment of the animal and environmental decontamination if necessary, and off-label use of the drugs approved for use in humans is quite common. Expand
Pharmacologic therapy of mycotic keratitis.
TLDR
The pharmacologic properties and clinical use of the currently available antifungal drugs are discussed and several new drugs and drug-delivery systems have been introduced in an attempt to improve the treatment outcomes. Expand
Update on the adverse effects of antimicrobial therapies in community practice.
TLDR
Current knowledge of harms from systemic oral antibiotics that are regularly used in family medicine is summarized in this article, finding it difficult to identify and ascribe exact probabilities of most harms. Expand
Critical synthesis of available data in Malassezia folliculitis and a systematic review of treatments
TLDR
The aim was to critically review the pathophysiology and clinical characteristics of Malassezia folliculitis, to describe laboratory methods that facilitate diagnosis and to systematically review treatment options. Expand
Cutaneous candidiasis – an evidence‐based review of topical and systemic treatments to inform clinical practice
TLDR
Clotrimazole, nystatin and miconazole were the most studied topical drugs and demonstrated equal good efficacy and mild adverse effects similar to combinations of antifungal, antibacterial and topical corticosteroids. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 51 REFERENCES
Drug safety assessment of oral formulations of ketoconazole
TLDR
Although oral ketoconazole is effective in treating fungal infections, the potential for drug interactions, endocrine dysregulation, and hepatotoxicity may outweigh its benefits and newer oral antifungals have similar or greater efficacy in treating dermatologic conditions and are associated with less risk. Expand
History of the development of azole derivatives.
  • J. Maertens
  • Biology, Medicine
  • Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2004
TLDR
These so-called 'second-generation' triazoles, including voriconazole, posaconazole and ravuconazole have greater potency and possess increased activity against resistant and emerging pathogens, in particular against Aspergillus spp. Expand
Chemotherapy for the systemic mycoses: the prelude to ketoconazole.
  • J. Utz
  • Medicine
  • Reviews of infectious diseases
  • 1980
TLDR
The introduction in 1957 of amphotericin B marked the first time there was an effective agent for such diseases as cryptococcosis, histoplasmosis, candidosis, and with lesser success, for coccidioidomycosis, mucormycosis; but, if patients are not monitored and controlled closely, the drug produces hypokalemic muscle weakness and cardiotoxicity. Expand
Ketoconazole: A Review of its Therapeutic Efficacy in Superficial and Systemic Fungal Infections
TLDR
Ketoconazole was effective in treating dermatophytic infections in guinea-pigs, and a wide variety of superficial and systemic candidal infections, and combined treatment of cryptococcosis with ketoconazoles plus amphotericin B tended to be more effective than either drug alone in reducing mortality. Expand
Liver injury associated with ketoconazole: Review of the published evidence
TLDR
It is difficult to determine the actual incidence or prevalence of liver injury during clinical use of ketoconazole as an antifungal, but there are not aware of published reports of significant ketoconAZole‐associated liver injury in volunteer study participants when ketconazole has been used as a CYP3A inhibitor in the context of clinical research on drug metabolism. Expand
Clinical Pharmacokinetics of Ketoconazole
TLDR
The half life of ketoconazole is dose-dependent, increases during long term treatment, suggesting auto-inhibition of metabolism, and the kinetics after oral administration fit a 2-compartment model. Expand
New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance
TLDR
This review attempts to deliver the most up-to-date knowledge on the mode of action and mechanisms of resistance to triazoles and echinocandins in fungal pathogens. Expand
Overview of medically important antifungal azole derivatives.
  • R. Fromtling
  • Medicine, Biology
  • Clinical Microbiology Reviews
  • 1988
TLDR
A major chemical group with antifungal activity, the azole derivatives, is examined and historical and state of the art information on the in vitro activity, experimental in vivo activity, mode of action, pharmacokinetics, clinical studies, and uses and adverse reactions are examined. Expand
Hepatic reactions associated with ketoconazole in the United Kingdom.
TLDR
Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury. Expand
Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings
TLDR
Rilpivirine has the potential to improve robustness and assess the clinical significance of interaction with antituberculosis drugs, and its long half-life suggests the potential for monthly dosing via nonoral routes, with promising early results from studies of a long-acting injectable formulation. Expand
...
1
2
3
4
5
...